Ginseng marc-derived low-molecular-weight neutral glucan SN-GOS ameliorates ulcerative colitis via inhibition of apoptosis and activation of autophagy in human intestinal HT-29 cells and DSS-induced inflammatory colitis mice.
This preclinical study suggests a ginseng-derived polysaccharide reduced inflammation and tissue injury in cell and mouse models of colitis, which could eventually inform dietary supplements or therapeutic research relevant to people with inflammatory bowel disease.
Researchers studying IBD treatments or functional food ingredients, clinicians following emerging preclinical research, and patients interested in diet- or supplement-based approaches (as early-stage interest).
What To Know
What To Know This study reports that a low-molecular-weight neutral glucan (SN-GOS) derived from ginseng marc showed anti-inflammatory effects in lab-grown human intestinal HT-29 cells and improved disease measures in a mouse model of DSS-induced colitis.
In cells, SN-GOS reduced markers of apoptosis, lowered TNF-α and IL-6 expression, decreased ROS, modulated MAPK signaling, and increased autophagy-related markers. In mice, oral SN-GOS (200–400 mg/kg) was associated with improved colon length, body weight, and tissue appearance.
The work is presented as preclinical laboratory research (cell lines and a chemical colitis mouse model) and does not report clinical testing in people. The authors frame SN-GOS as a potential functional food ingredient rather than an approved therapy.
If you have Crohn’s disease or ulcerative colitis, this is an early-stage finding that may point to future dietary or supplement research; it is not evidence to support using ginseng marc products as treatment. Talk with your clinician before making changes to diet or supplements, especially if you are on immunosuppressive medications.
Results come from cell culture and a DSS mouse model; such findings often do not translate directly to human benefit. The article is an abstract-level summary of laboratory research published in Carbohydrate Research; it does not report clinical trials or safety data in humans.
